Amyris Inc (AMRS)

0.53
0.01 1.10
NASDAQ : Basic Materials
Prev Close 0.53
Open 0.52
Day Low/High 0.51 / 0.54
52 Wk Low/High 0.31 / 2.57
Volume 2.14M
Avg Volume 2.26M
Exchange NASDAQ
Shares Outstanding 263.02M
Market Cap 136.77M
EPS -1.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Mattel CEO Georgiadis Expected to Drive Tech Growth

Mattel CEO Georgiadis Expected to Drive Tech Growth

Mattel's (MAT) naming of former Google president of the Americas Margaret Georgiadis as CEO shows the toy maker wants to make a big splash in the tech world.

Amyris & NIKKOL GROUP Create Leading Cosmetics Ingredient Joint Venture

Amyris & NIKKOL GROUP Create Leading Cosmetics Ingredient Joint Venture

Leading Global Cosmetic Ingredient Innovator Joins Amyris to Accelerate Growth of Leading Cosmetic Skin Care Ingredient Business

Amyris Partners With Queensland To Create The Leading Industrial Biotechnology Hub In Southeast Asia

Amyris Partners With Queensland To Create The Leading Industrial Biotechnology Hub In Southeast Asia

Government and Local Sugarcane Industry Partners with Amyris to Produce Sustainable Ingredients for the Personal Care and Nutraceutical Markets

Amyris Signs Multi-Year Collaboration Extension With Kuraray

Amyris Signs Multi-Year Collaboration Extension With Kuraray

Includes Joint Marketing of Products

Amyris Achieves Key Milestone In Major Drug Discovery Collaboration

Amyris Achieves Key Milestone In Major Drug Discovery Collaboration

Industry Leading µPharm Technology Platform Delivers Initial Development Work in Just Four Months for New Oncology Drug Development

Amyris Reports Third Quarter 2016 Results

Amyris Reports Third Quarter 2016 Results

Record Revenue, Lower SG&A Expenses and Strong Outlook

BIOSSANCE™ To Launch In Sephora Stores

BIOSSANCE™ To Launch In Sephora Stores

Fast Growing, Sustainable Skin Care Brand Partners with Leading Prestige Specialty Beauty Retailer to Meet Growing Consumer Demand for Sustainable Skin Care Products

Amyris Enters Collaboration With Top 10 Pharmaceutical Company For Biosynthetic Drug Discovery

Amyris Enters Collaboration With Top 10 Pharmaceutical Company For Biosynthetic Drug Discovery

Amyris's Leading µPharm™ Platform Focused on Rapid Discovery of Novel Antibiotic Compound Target

Interesting AMRS Call Options For June 2017

Interesting AMRS Call Options For June 2017

Investors in Amyris, Inc. saw new options begin trading this week, for the June 2017 expiration.

Amyris Agrees To Collaboration Terms with Leading Global Food Ingredients And Nutraceuticals Partner

Amyris Agrees To Collaboration Terms with Leading Global Food Ingredients And Nutraceuticals Partner

Includes up to $30 Million Collaboration Investment, $100 Million in Annual Revenue and Participation in Industrial Fermentation Facilities in Asia

Amyris In Partnership With Boticario Group Named Gold Winner By Cosmetics Design For Breakthrough Ingredient - Neossance® Hemisqualane

Amyris In Partnership With Boticario Group Named Gold Winner By Cosmetics Design For Breakthrough Ingredient - Neossance® Hemisqualane

Industry Recognition of Neossance and Accelerated Customer Adoption Continues to Fuel Record Sales Growth

Amyris Wins Three-Year, Multi-Million-Dollar Contract From U.S. Department Of Energy To Further Manufacturing Of Cellulose-Derived Farnesene

Amyris Wins Three-Year, Multi-Million-Dollar Contract From U.S. Department Of Energy To Further Manufacturing Of Cellulose-Derived Farnesene

Expected to Expand Global Availability of Farnesene for Variety of Applications

Amyris Reports Second Quarter 2016 Results

Amyris Reports Second Quarter 2016 Results

Strongest Operational Execution to Date while Successfully Moving the Business Beyond Biofuels